CSL Behring Wins Approval for ANDEMBRY in Japan
CSL Behring K.K. has achieved a significant milestone with the approval of ANDEMBRY (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens. This innovative therapy serves as a crucial new treatment option for the prevention of acute attacks of hereditary angioedema (HAE), a debilitating genetic condition characterized by swelling episodes that can be life-threatening.
Groundbreaking Therapy for Hereditary Angioedema
ANDEMBRY is recognized as the first and only fully human monoclonal antibody in Japan focused on inhibiting activated Factor XII (FXIIa). This mechanism is essential, as FXIIa is known to initiate a cascade leading to angioedema. The approval comes following impressive results from the pivotal Phase 3 VANGUARD trial, which provided compelling evidence of ANDEMBRY's safety and efficacy.
Commitment to HAE Community
CSL has demonstrated enduring devotion to enhancing the lives of those affected by HAE for over four decades. The company is committed to pioneering advancements in HAE management and ensuring patients have access to groundbreaking therapies such as ANDEMBRY. "This advancement underscores our dedication to innovative solutions in healthcare," shared Bill Mezzanotte, MD, Executive Vice President of CSL's R&D division.
The Impact of HAE and Patient Statistics
Hereditary angioedema is classified as a rare condition that impacts a small segment of the population, with approximately 430 diagnosed patients currently receiving treatment in Japan alone. The condition often leads to painful and unpredictable swelling in various body areas, presenting significant challenges for those affected. Global prevalence estimates suggest that roughly 1 in 50,000 individuals may have HAE, which indicates about 2,500 potential patients in Japan. These statistics underscore the importance of innovative therapies like ANDEMBRY for managing HAE effectively.
Details of ANDEMBRY Approval
ANDEMBRY's approval in Japan aligns with similar endorsements from regulatory agencies in Australia, the United Kingdom, and the European Union in early 2025. CSL Behring’s effort in developing and obtaining approval for this product reflects its commitment to improving treatment modalities for rare diseases. The drug has shown to be effective when administered once a month, making it a convenient option for long-term management of HAE.
Usage and Administration
The recommended dosage for ANDEMBRY begins with a loading dose of 400 mg followed by monthly doses of 200 mg for adults and adolescents over the age of 12. This straightforward administration method, which utilizes a pre-filled pen, facilitates ease of use, allowing patients and caregivers to manage the therapy effectively.
Overview of CSL Behring K.K.
CSL Behring K.K. operates as a part of CSL Limited, a global leader renowned for the development of critical therapies for rare and serious diseases. The company’s efforts focus primarily on immunology and rare diseases while ensuring high-quality medicines reach those in need. CSL’s dedication to research and innovation positions it well within the competitive biotechnology landscape.
Frequently Asked Questions
What is ANDEMBRY used for?
ANDEMBRY is used for the prevention of acute attacks of hereditary angioedema (HAE).
How does ANDEMBRY work?
ANDEMBRY inhibits activated Factor XII (FXIIa), which initiates the processes leading to angioedema attacks.
What are the dosage recommendations for ANDEMBRY?
The usual initial loading dose is 400 mg, followed by monthly administrations of 200 mg.
What is the significance of the approval in Japan?
This approval provides a new treatment option for HAE patients in Japan and reflects CSL's commitment to improving health outcomes.
Who is leading CSL's research and development?
Bill Mezzanotte, MD, is the Executive Vice President overseeing the R&D division at CSL.
